Global Search

Oncology • Leukemia

FLT3 (ITD/TKD) / IDH1 / IDH2

Oncology • Mastocytosis

KIT

Oncology • Thyroid

BRAF

Oncology • Brain

IDH1 / IDH2

Oncology • Leukemia

TP53

Oncology • Biliary

ERBB2 (HER2)

Oncology • Breast

BRCA1 / BRCA2 / ERBB2 (HER2) / ESR1 / PIK3CA

Oncology • Cervix

PD-L1

Oncology • Bile Duct

FGFR2 / IDH1

Oncology • Leukemia

t(9;21) Philadelphia chromosome

Oncology • Colorectal

ACVR2A / BRAF / BTBD7 / DIDO1 / EGFR (HER1) / KRAS / MRE11 / NRAS / RYR3 / SEC31A / SULF2 / deficient mismatch repair (dMMR) proteins

Neurology • Muscle

AAV Antibodies

Oncology • Endometrium

Not MSI-High / deficient mismatch repair (dMMR) proteins / proficient mismatch repair (pMMR) proteins

Oncology • Ovary/Peritoneum

FOLR1

Oncology • Esophagus

PD-L1

Oncology • Lymphoma

EZH2

Oncology • Stomach/GEJ

ERBB2 (HER2)

Oncology • Stomach/GEJ

Claudin 18 (CLDN18) / PD-L1

Oncology • GIST

PDGFRA

Oncology • Head & Neck

PD-L1

Hematology • Blood

AAV Antibodies

Hematology • Blood

Antithrombin III / Concizumab

Oncology • Brain

BRAF

Oncology • Thyroid

RET

Oncology • Melanoma

BRAF

Oncology • Prostate

ATM / BRCA1 / BRCA2 / Homologous recombination repair (HRR) genes

Oncology • Colorectal

BRAF

Hematology • Blood

AAV Antibodies

Oncology • Bone Marrow

IDH1 / PDGFRB

Oncology • Lung

ALK / BRAF / EGFR (HER1) / ERBB2 (HER2) / KRAS / MET / PD-L1 / RET / ROS1

Hematology • Blood

Liver iron concentration imaging

Endocrinology • Metabolic

LEPR / PCSK1 / POMC

Oncology • Ovary

BRCA1 / BRCA2 / HRD

Oncology • Pancreas

BRCA1 / BRCA2

Oncology • Prostate

BRCA1 / BRCA2

Oncology • Solid Tumor

MSI-High / NTRK1 / NTRK2 / NTRK3 / RET / TMB / deficient mismatch repair (dMMR) proteins

Oncology • Soft Tissue

HLA / Melanoma-associated antigen 4 (MAGE-A4)

Oncology • Thyroid

RET

Oncology • Breast

PD-L1

Oncology • Bladder

FGFR3 / PD-L1

Oncology • Eye

HLA

serotype 5, serotype rh74

Duchenne Muscular Dystrophy (DMD), Hemophilia A Patients, Moderate to severe Hemophilia B patients

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

gene rearrangements, protein expression

Non-Small Cell Lung Cancer (NSCLC)

Functionally active Antithrombin III

Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors

alterations (including mutations)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

V600, V600 and BRAF fusions, V600E, V600E and V600K, V600E or V600K

Anaplastic Thyroid Cancer (ATC), Colorectal Cancer (CRC), Low-Grade Glioma, Melanoma, Metastatic Colorectal Cancer (mCRC), Non-Small Cell Lung Cancer (NSCLC)

alterations (including mutations)

Breast Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

alterations (including mutations)

Breast Cancer, Metastatic Castrate Resistant Prostate Cancer (mCRPC), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Claudin 18 (CLDN18) protein expression (≥75% viable tumor cells (% TC) staining)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Tissue factor pathway inhibitor antagonist

Hemophilia A patients with or without factor VIII inhibitors and Hemophilia B patients with or without IX inhibitors

MLH1, PMS2, MSH2 and MSH6

Colorectal Cancer (CRC), Endometrial Carcinoma (EC), Solid Tumors

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Exon 19 deletion or exon 21 L858R substitution mutation, Exon 19 deletions or exon 21 L858R, and T790M, Exon 20 insertions, L861Q, G719X and S7681, T790M, protein expression

Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)

Activating Mutations (SNVs And Exon 20 Insertions), Activating mutations in the tyrosine kinase domain (SNVs in exons 18-21 and exon 20 insertions), HER-2 protein overexpression, HER2 ultralow expression (IHC 0 with membrane staining), HER2-low expression (IHC 1+ or IHC 2+/ISH non-amplified), gene amplification

Biliary Tract Cancer, Breast Cancer, Gastric and Gastroesophageal Cancer, Non-Small Cell Lung Cancer (NSCLC)

ESR1 missense mutations between codons 310 and 547

Breast Cancer

Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene

Follicular Lymphoma Tumor

fusions and select rearrangements

Cholangiocarcinoma

Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)

Urothelial Cancer

ITD mutations and TKD mutations D835 and I836

Acute Myeloid Leukemia (AML)

protein expression

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Eligible alleles: HLA-A*02:01, HLA-A*02:02, HLA-A*02:03 or HLA-A*02:06 and their P-group alleles. Exclusion alleles: HLA-A*02:05 and its P-group alleles., HLA-A*02:01

Synovial sarcoma, Uveal Melanoma

BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score

Ovarian Cancer

IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations, R132 mutations (R132C, R132H, R132G, R132S, and R132L), Single nucleotide variants

Acute Myeloid Leukemia (AML), Astrocytoma and Oligodendroglioma, Cholangiocarcinoma, Myelodysplastic Syndromes (MDS)

IDH1 R132C, IDH1 R132G, IDH1 R132H, IDH1 R132L, IDH1 R132S, IDH2 R172M, IDH2 R172K, IDH2 R172W, IDH2 R172S, and IDH2 R172G mutations, R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W

Acute Myeloid Leukemia (AML), Astrocytoma and Oligodendroglioma

D816V

Aggressive Systemic Mastocytosis

G12A, G12D, G12R, G12C, G12S, G12V, G13D, G12C, KRAS wild-type (absence of mutations in codons 12 and 13), Mutations in codons 12 and 13 of KRAS gene, wild-type (absence of mutations in exons 2, 3 and 4)

Colorectal Cancer (CRC), Non-Small Cell Lung Cancer (NSCLC)

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

based on the proton transverse relaxation rate of MRI images

Non-Transfusion-Dependent Thalassemia

MAGE-A4 protein overexpression

Synovial sarcoma

MET protein expression (>= 50% of tumor cells exhibiting strong membrane and/or cytoplasmic staining 3+), single nucleotide variants and indels that lead to MET exon 14 skipping

Non-Small Cell Lung Cancer (NSCLC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High

Solid Tumors

Not Microsatellite Instability-High (Not MSI-H)

Endometrial Carcinoma (EC)

wild-type (absence of mutations in exons 2, 3 and 4)

Colorectal Cancer (CRC)

fusions

Solid Tumors

fusions

Solid Tumors

fusions

Solid Tumors

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

protein expression, protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area), protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%]), protein expression (tumor cell staining ≥1%), protein expression [Tumor Proportion Score (TPS) ≥ 50%]

Cervical Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Triple-Negative Breast Cancer (TNBC), Urothelial Cancer

D842V mutation

Gastrointestinal Stromal Tumors (GIST)

PDGFRB gene rearrangement at 5q31~33

Myelodysplastic Syndromes (MDS)

AKT1/PTEN alterations, C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y, alterations (including mutations)

Breast Cancer

Variants (Pathogenic/Likely Pathogenic) and Variants of Uncertain Significance

Obesity

MLH1, PMS2, MSH2 and MSH6

Endometrial Carcinoma (EC)

RET mutations (SNVs, MNVs, and deletions), fusions

Medullary Thyroid Cancer (MTC), Non-Small Cell Lung Cancer (NSCLC), Solid Tumors, Thyroid Cancer (TC)

fusions

Non-Small Cell Lung Cancer (NSCLC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

Microsatellite instability-High (MSI-H)

Colorectal Cancer (CRC)

BCR-ABL fusion

Chronic Myeloid Leukemia (CML)

TMB ≥ 10 mutations per megabase

Solid Tumors

Deletion chromosome 17p (17p-)

B-cell Chronic Lymphocytic Leukemia (CLL)

Johnson & Johnson

Genentech

Novo Nordisk

Takeda

Blueprint Medicines

Johnson & Johnson

Pfizer

AbbVie

Sarepta Therapeutics

AbbVie

Daiichi Sankyo / AstraZeneca

Xcovery Holdings, Inc.

Eli Lilly

Novartis

Rigel Pharmaceuticals

Boehringer Ingelheim

Novartis

Genentech

Boehringer Ingelheim

Bristol Myers Squibb / Servier Pharmaceuticals

Rhythm Pharmaceuticals

AstraZeneca

AstraZeneca

GSK

Genentech

Merck

Bristol Myers Squibb

Bristol Myers Squibb

Regeneron

Pfizer

Amgen

AstraZeneca / Merck

Novartis

Day One Biopharmaceuticals, Inc.

Bristol Myers Squibb

Bristol Myers Squibb

Stemline Therapeutics

Incyte

Genentech

Novartis

Sanofi

Eli Lilly

Rigel Pharmaceuticals

BioMarin

Genentech

Pharma&

Johnson & Johnson

Novartis

Novartis

Novartis

AstraZeneca

Pfizer

Genentech

Novartis

Ipsen

Adaptimmune

Genentech

Merck KGaA

Servier Pharmaceuticals

Daiichi Sankyo

Amgen

Genentech / AbbVie

Bayer

Pfizer

Servier Pharmaceuticals

Astellas Pharma

Pfizer

Astellas Pharma

Dizal Pharmaceutical

Genentech

Jazz Pharmaceuticals

Novartis

ARUP Laboratories, Inc.

Abbott Molecular, Inc.

Abbott Molecular, Inc.

Resolution Bioscience

Myriad Genetics

Leica Biosystems

EntroGen, Inc.

Randox Laboratories Ltd.

Dako North America, Inc. (Agilent Technologies, Inc.)

Resonance Health Analysis Services Pty Ltd

Foundation Medicine, Inc.

Foundation Medicine, Inc.

Guardant Health, Inc.

Dako Denmark A/S (Agilent Technologies, Inc.)

Dako Denmark A/S (Agilent Technologies, Inc.)

Siemens Healthcare Diagnostic Products GmbH

Biocartis US Inc.

ARUP Laboratories, Inc.

Invivoscribe Technologies, Inc.

Agilent Technologies, Inc.

Caris Life Sciences

Dako Omnis (Agilent Technologies, Inc.)

MolecularMD Corporation

Myriad Genetics

Pillar Biosciences, Inc.

Life Technologies Corporation (ThermoFisher Scientific)

Life Technologies Corporation (ThermoFisher Scientific)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Dako North America, Inc. (Agilent Technologies, Inc.)

Dako North America, Inc. (Agilent Technologies, Inc.)

ARUP Laboratories, Inc.

Prevention Genetics

Abbott Molecular, Inc.

Quest Diagnostics

One Lambda, Inc. (ThermoFisher Scientific)

Illumina, Inc.

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Ventana Medical Systems, Inc. (Roche Diagnostics)

Abbott Molecular, Inc.

Abbott Molecular, Inc.

Roche Molecular Systems, Inc. (Roche Diagnostics)

Roche Molecular Systems, Inc. (Roche Diagnostics)

Roche Molecular Systems, Inc. (Roche Diagnostics)

Roche Molecular Systems, Inc. (Roche Diagnostics)

Labcorp

QIAGEN GmbH (Qiagen)

Qiagen Manchester, Ltd. (Qiagen)

Qiagen Manchester, Ltd. (Qiagen)

Qiagen Manchester, Ltd. (Qiagen)

QIAGEN GmbH (Qiagen)

QIAGEN GmbH (Qiagen)

Tempus